{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:48:23Z","timestamp":1780440503611,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.004","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T12:13:43Z","timestamp":1614946423000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-2502","authenticated-orcid":false,"given":"Zachary D.","family":"Epstein-Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_5","key":"10.1053\/j.seminhematol.2021.02.004_bib0001","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.004_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.004_bib0003","first-page":"4150","article-title":"Differential outcome of patients with primary refractory vs. relapsed peripheral T-cell lymphoma: analysis from a prospective multicenter US cohort study","volume":"128","author":"Lansigan","year":"2016","journal-title":"Am Soc Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.004_bib0004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"Mckinney","year":"2017","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.004_bib0005","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","article-title":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets","volume":"119","author":"Travert","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.004_bib0006","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0007","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.004_bib0008","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"5583","key":"10.1053\/j.seminhematol.2021.02.004_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110\u03b4 PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-32634-5","article-title":"Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma","volume":"8","author":"Mamand","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0011","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.004_bib0012","first-page":"1415","article-title":"Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T\u2011cell lymphoma","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1053\/j.seminhematol.2021.02.004_bib0013","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.humpath.2018.08.025","article-title":"Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis","volume":"83","author":"Liu","year":"2019","journal-title":"Hum Pathol"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.004_bib0014","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.004_bib0015","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/blood-2019-125507","article-title":"First-in-human study of the EZH1\/2 dual inhibitor valemetostat in relapsed or refractory non-hodgkin lymphoma (NHL)-updated results focusing on adult T-cell leukemia-lymphoma (ATL)","volume":"134","author":"Morishima","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.004_bib0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0017","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1158\/0008-5472.CAN-18-1421","article-title":"Stabilized peptide HDAC inhibitors derived from HDAC1 substrate H3K56 for the treatment of cancer stem\u2013like cells in vivo","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0018","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.4049\/jimmunol.177.8.5122","article-title":"The p110\u03b4 isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells","volume":"177","author":"Okkenhaug","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2021.02.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0021","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-140412","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: dose optimization efficacy update and expansion phase initial results","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.004_bib0023","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.004_bib0024","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0025","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/leu.2016.13","article-title":"JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma","volume":"30","author":"Nairism\u00e4gi","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.004_bib0026","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/gcc.22141","article-title":"Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia","volume":"53","author":"Bergmann","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.004_bib0028","doi-asserted-by":"crossref","first-page":"13897","DOI":"10.1073\/pnas.94.25.13897","article-title":"Proliferation of adult T cell leukemia\/lymphoma cells is associated with the constitutive activation of JAK\/STAT proteins","volume":"94","author":"Takemoto","year":"1997","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.004_bib0029","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/gcc.22104","article-title":"Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma","volume":"52","author":"Feldman","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.004_bib0030","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.004_bib0031","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4049\/jimmunol.165.3.1300","article-title":"B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase","volume":"165","author":"Pogue","year":"2000","journal-title":"J Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.004_bib0032","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.4049\/jimmunol.152.10.4758","article-title":"Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling","volume":"152","author":"Chan","year":"1994","journal-title":"J Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0033","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.004_bib0034","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"41","key":"10.1053\/j.seminhematol.2021.02.004_bib0035","doi-asserted-by":"crossref","first-page":"E2794","DOI":"10.1073\/pnas.1205742109","article-title":"TCR signaling via Tec kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8+ T-cell differentiation","volume":"109","author":"Nayar","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0036","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/1074-7613(95)90065-9","article-title":"Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk","volume":"3","author":"Liao","year":"1995","journal-title":"Immunity"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0037","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.004_bib0038","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-16-1996","article-title":"T-cell receptor signaling activates an ITK\/NF-\u03baB\/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2021.02.004_bib0039","article-title":"CPI-818, an oral interleukin-2-inducible t-cell kinase inhibitor. pre-clinical characterization and interim results of a phase I\/Ib dose-escalation trial in patients with relapsed\/refractory T-cell lymphoma","author":"Mobasher","year":"2020","journal-title":"T-Cell Lymphoma Forum"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.004_bib0040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-05-0146","article-title":"Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures","volume":"4","author":"Mahadevan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.004_bib0041","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","volume":"37","author":"Qi","year":"2013","journal-title":"Leuk Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0042","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O'Connor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.004_bib0043","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase\u2013positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.004_bib0044","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in patients with advanced anaplastic lymphoma kinase\u2013rearranged anaplastic large-cell lymphoma","volume":"126","author":"Richly","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.02.004_bib0045","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.004_bib0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0047","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.004_bib0048","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A phase I\/II study to examine the safety and efficacy of pembrolizumab 200 Mg fixed dose administered every 3 weeks (Q3W) in combination with romidepsin in relapsed or refractory peripheral T-cell lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.004_bib0049","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-19-2152","article-title":"Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-cell lymphoma: results of a phase I dose-escalation study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.004_bib0051","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0052","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.3324\/haematol.2018.187617","article-title":"A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"103","author":"Strati","year":"2018","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0053","first-page":"1515","article-title":"A phase 1\/2 study of oral 5-azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T-cell lymphoma (PTCL)","volume":"130","author":"Falchi","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.004_bib0054","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY. 15 study","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/blood.V130.Suppl_1.821.821","article-title":"A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas","volume":"130","author":"Mehta-Shah","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.004_bib0056","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.3324\/haematol.2019.220012","article-title":"A phase 1 trial of alisertib and romidepsin for relapsed\/refractory aggressive B-cell and T-cell lymphomas","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0057","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026575","article-title":"Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer","volume":"6","author":"Laugesen","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.004_bib0058","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/bloodadvances.2019001256","article-title":"Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma","volume":"4","author":"Pikman","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.004_bib0059","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2021.02.004_bib0060","doi-asserted-by":"crossref","first-page":"A161","DOI":"10.1093\/ajcp\/138.suppl1.147","article-title":"EZH2 expression is increased in neoplastic T cells as compared with reactive lymphocytes and differs in different subtypes of T-cell lymphoma","volume":"138","author":"Dhiran","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.004_bib0061","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0062","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.13170","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma","volume":"168","author":"Cheminant","year":"2014","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.004_bib0063","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0064","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.004_bib0065","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1080\/10428194.2019.1627541","article-title":"Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1\u2013azacitidine induces only lymphoma remission","volume":"60","author":"Tobiasson","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0066","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2018-99-117210","article-title":"Long-term follow-up of patients with mantle cell lymphoma treated with venetoclax monotherapy","volume":"132","author":"Davids","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.004_bib0067","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.004_bib0068","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2016.49","article-title":"Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance","volume":"30","author":"Spinner","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.004_bib0069","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2014-09-601567","article-title":"MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice","volume":"124","author":"Grabow","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.004_bib0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2018-07-865527","article-title":"Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0071","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1182\/blood-2018-99-116780","article-title":"Preliminary results of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, in two phase IIa dose expansion cohorts in relapsed\/refractory TP53 wild-type peripheral T-cell lymphoma","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.004_bib0072","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.004_bib0073","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.004_bib0074","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.004_bib0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2021.02.004_bib0076","doi-asserted-by":"crossref","unstructured":"Witzig T, Sokol L, Kim W, et al. Tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from a phase 2 study. 2020.","DOI":"10.1002\/hon.32_2629"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.004_bib0077","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2018-99-116277","article-title":"Tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-Cell Lymphoma (PTCL): preliminary results from an open-label, phase 2 study","volume":"132","author":"Witzig","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1053\/j.seminhematol.2021.02.004_bib0078","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/01.HS9.0000562304.50732.0a","article-title":"PS1002 RHOE, CXCL12 AND CXCR3 may identify complete responses in acute myeloid leukemia patients treated with tipifarniB","volume":"3","author":"Gualberto","year":"2019","journal-title":"HemaSphere"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.004_bib0079","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41379-019-0279-8","article-title":"Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified","volume":"33","author":"Laginestra","year":"2020","journal-title":"Modern Pathol"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.004_bib0080","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-Cell Lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:33Z","timestamp":1758522513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000147"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}